Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - October 20, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/20/17 - Arcus Biosciences Announces Option and License Agreement with Taiho Pharmaceutical Co. Ltd.
Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today that it has entered into an option and license agreement with Taiho Pharmaceutical Co. Ltd., for the potential development and commercialization of product candidates in Arcus s portfolio in Japan and
9/20/17 - Bronchial Thermoplasty Trial Finds Positive Outcomes for Asthma
Results from a three-year follow-up of patients administered bronchial thermoplasty found that patients experienced similar reductions in severe exacerbations, hospitalizations, and emergency room visits when compared to an earlier clinical trial.
9/20/17 - Downstream Processing Market at a CAGR of 16.4% to 2021
Global downstream processing Market Size, Hit CAGR for forecast period 2016-2021 The global downstream processing market is projected to reach USD 22.03 billion by 2021 from USD 10.32 billion in 2016, at a CAGR of 16.4% from 201...
9/20/17 - High-Throughput Process Development Market: Merck Millipore, Bio-Rad Laboratories Inc, Eppendorf AG, Perkinelmer
High-Throughput Process Development Instruments Market Size, By Country, 2017-2021 (USD Million) The global high-throughput process development market is expected to reach USD 19.78 billion in 2021 from USD 9.91 billion in 2016, ...
9/19/17 - 41 states to investigate pharmaceutical companies over opioids
The coalition issued subpoenas seeking information from opioid manufacturers Endo International, Janssen Pharmaceuticals, Teva Pharmaceuticals and Allergan, as well as additional subpoenas to Purdue Pharma. In addition, the group is demanding documents from distribution companies AmerisourceBergen, Cardinal Health and McKesson.
9/19/17 - 4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for Gene Therapy IND Candidate for Cystic Fibrosis
4 D Molecular Therapeutics, a leader in adeno-associated virus gene therapy vector discovery and product development, today announced $3 million in additional funding from Cystic Fibrosis Foundation Therapeutics Inc., the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to expand ongoing efforts to develop an I
9/19/17 - 65 AXUMIN PET radiopharmaceutical used for PET imaging
Office Address: Department of Veterans Affairs; VA Sierra Pacific Network; VA Northern California HealthCare System; 5342 Dudley Blvd. Bldg 98; McClellan CA 95652-1012. Place of Performance: VA Palo Alto Healthcare System; 3801 Miranda Ave., Bldg. 100; Palo Alto, CA. Description: Department of Veterans Affairs.
9/19/17 - Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer [Palestine News Network]
Dr. Srivastava brings to Abide more than 15 years of experience with a strong background in the biopharmaceutical industry and Wall Street. Dr. Srivastava has more than 15 years of experience as a senior executive in the biopharmaceutical industry and on Wall Street. Prior to that role, Dr. Srivastava spent over a decade on Wall Street as a Senior
9/19/17 - ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 10:00 a.m. Eastern Time i
9/19/17 - Acceleron Announces Proposed Public Offering of Common Stock
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offer
9/19/17 - ACCELERON PHARMA INC FILES (8-K) Disclosing Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 18, 2017, Acceleron Pharma Inc. and Celgene Corporation entered into an Amended and Restated Collaboration, License and Option Agreement that amends and restates their existing Collaboration, License and Option Agreement, dated as of February 20, 2008 and amended as of August 2, 201
9/19/17 - Acceleron Showcases Vision and Strategy at 2017 R&D Day
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, hosted its Research and Development Day in New York City today. The Company discussed clinical development plans to build therapeutic area leadership, and its long-term strategy to advance key prog
9/19/17 - Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it has amended the sotatercept development and commercialization collaboration agreement with Celgene Corporation, originally executed on February 20, 2008. Sotatercept shows...
9/19/17 - Acer Therapeutics and Opexa Therapeutics Close Merger and Financing
Acer Therapeutics Inc.,, a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, announced that today it completed the merger with Opexa Therapeutics, Inc., under which the stockholders of Acer become holders of 88.8% of combined
9/19/17 - Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
Release date- 18092017- BOTHELL, Wash. and VANCOUVER, British Columbia- Achieve Life Sciences, Inc., a clinical stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a share purchase agreement with Lincoln Park Capital Fund, LLC pursuant to
9/19/17 - Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, today announced that results from a Phase 2 clinical trial evaluating two concentrations of its drug candidate A-101 for the treatment of facial seborrheic keratosis lesions have been published in the journal Dermatologic Surgery. The FDA s Prescription Drug User Fee Ac
9/19/17 - Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of open-angle glaucoma and other diseases of the eye, today announced the appointment of Tori Arens as Vice President of Drug Product Manufacturing, reporting to Kenneth...
9/19/17 - AgeneBio Receives NIH Grant to Initiate Phase 3 HOPE4MCI Trial to Treat MCI Due to Alzheimer's Disease
This grant builds on the previous NIH grant for the HOPE4MCI trial that established a public-private partnership among the NIA, Johns Hopkins University, and AgeneBio for the HOPE4MCI trial. "With the award of this additional funding from the NIH, we will immediately initiate the Phase 3 trial start-up with an initial cohort of clinical sites and
9/19/17 - Agilent Announces Expanded Use of Cancer Diagnostic in the United States
Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which patients with locally adv
9/19/17 - Agilent Announces Expanded Use of Cancer Diagnostic in the United States; .Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications
SANTA CLARA, Calif. Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which pat
9/19/17 - Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive Officer Dr. David Horn Solomon and Chief Operations Officer Clive Richardson will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday September 26, 2017 in New York City. To access the live webcast of t
9/19/17 - Alabama AG subpoenas opioid records from drug companies [The Anniston Star, Ala.]
Sept. 19 Forty-one state attorneys general, including Alabama's Steve Marshall, sent letters to several drug companies Tuesday demanding information on their role in the spread of opioid abuse. Another company, Purdue Pharma, received a "supplementary" investigative demand, according to Marshall's announcement possibly a sign that the states wa
9/19/17 - Albireo to Present at Investor Conferences in September
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following investor conferences in September:. Cantor Fitzgerald Global Healthcare Conference Location: InterContinental New York Barclay in
9/19/17 - Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced the pricing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $7.25 per share.
9/19/17 - Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference
Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, CEO, will present at the Sidoti& Company Fall 2017 Conference at the New York Marriott Marquis in New York, New York. Alimera Sciences presentation will take place Thursday, September 28th at 9:0
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415